Trial Profile
An open phase III trial with letrozole as early adjuvant treatment of postmenopausal patients with primary breast cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Letrozole (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Oct 2010 Planned end date changed from 1 Apr 2013 to 1 Jul 2010 as reported by ClinicalTrials.gov.
- 18 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.